International Journal of General Medicine (Dec 2019)
Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges
Abstract
Nika Mohannak,1 Gemma Pattison,2 Kathryn Hird,1 Merrilee Needham1,3,4 1School of Medicine, The University of Notre Dame, Fremantle, Western Australia, Australia; 2Department of Speech Pathology, Royal Perth Hospital, Perth, Western Australia, Australia; 3Department of Neurology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia; 4Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, AustraliaCorrespondence: Merrilee NeedhamInstitute for Immunology and Infectious Diseases, Murdoch University, Building 390 Discovery Way, Murdoch, WA 6150, AustraliaTel +61 8 9360 1334Fax +61 8 9360 1380Email [email protected]: Dysphagia in inclusion body myositis (IBM) is common and associated with increased mortality and morbidity due to aspiration pneumonia, malnutrition and dehydration. There is currently no consensus on treatment of dysphagia in IBM and outcomes are variable depending on timing of intervention, patient preference and available expertise. There is a paucity of research exploring the pathophysiology of dysphagia in IBM and appropriate investigations. Increased knowledge of the aetiopathogenesis is likely to change the approach to treatment as well as improve the quality of life for patients. This review explores the epidemiology and pathophysiology of dysphagia in IBM and the currently available treatment strategies.Keywords: inflammatory myopathies, swallowing, epidemiology, pathophysiology, treatment, diagnosis
